Immunosuppression clinical trials

Explore recruiting immunosuppression clinical trials.

Recruiting immunosuppression studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunosuppression trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg patients that have received an HLA-A2pos liver transplant.

Belgium, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Cell-based immunotherapy in solid organ transplantation to minimize systemic immunosuppression

Sweden

Phase I and Phase II (Integrated)- Bioequivalence Study EU CTIS Study details

INFINITY - Effect of interferon gamma as a treatment for post-aggressive immunosuppression in intensive care units, a randomized Bayesian double-blind controlled trial versus placebo

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Immunogenicity of 9-valent HPV vaccine in immunocompromised children and adolescents

Spain

Phase III and phase IV (Integrated) EU CTIS Study details

A multicenter, open, prospective, randomized, parallel-group, 12-month trial of REduced immunosuppression for oLdEr AdultS kidnEy transplant recipients: the RELEASE study.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Immunosuppression trials by city

Immunosuppression in Toronto Immunosuppression in Vancouver Immunosuppression in Montreal Immunosuppression in Calgary Immunosuppression in Edmonton Immunosuppression in Ottawa Immunosuppression in Winnipeg Immunosuppression in Quebec City Immunosuppression in Hamilton Immunosuppression in Kitchener Immunosuppression in London Immunosuppression in Halifax Immunosuppression in New York Immunosuppression in Los Angeles Immunosuppression in Chicago Immunosuppression in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease